<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03244462</url>
  </required_header>
  <id_info>
    <org_study_id>18387</org_study_id>
    <secondary_id>2016-004393-18</secondary_id>
    <nct_id>NCT03244462</nct_id>
  </id_info>
  <brief_title>Food Effect, Oral &amp; Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate</brief_title>
  <official_title>Open Label, Randomized, Cross-over Study to Explore the Pharmacokinetics of BAY1834845 After Oral and Intravenous Dosing, Including Food Effect and Absolute Bioavailability (Part A), and to Investigate the Effect of BAY1834845 on the Pharmacokinetics of Orally Administered Methotrexate (Part B) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to explore the effect of food on the oral pharmacokinetics, the
      intravenous pharmacokinetics and the absolute bioavailability of BAY1834845. Furthermore,
      this study will investigate the effect of BAY1834845 on the pharmacokinetics of orally
      administered methotrexate in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Anticipated">May 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (Area under the concentration-versus-time curve from zero to infinity after single (first) dose) of BAY1834845 after oral administration of BAY1834845 to subjects in fed/fasted state</measure>
    <time_frame>Multiple timepoints up to day 7</time_frame>
    <description>in study part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration attained (Cmax) of BAY1834845 after oral administration of BAY1834845 to subjects in fed/fasted state</measure>
    <time_frame>Multiple timepoints up to day 7</time_frame>
    <description>in study part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL) of [13C6] BAY1834845 after intravenous administration</measure>
    <time_frame>Multiple timepoints up to day 7</time_frame>
    <description>in study part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady state (Vss) of [13C6] BAY1834845 after intravenous administration</measure>
    <time_frame>Multiple timepoints up to day 7</time_frame>
    <description>in study part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute oral bioavailability (F) of BAY1834845 in the fasted state</measure>
    <time_frame>Multiple timepoints up to day 7</time_frame>
    <description>in study part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of methotrexate in plasma in presence/absence of BAY1834845</measure>
    <time_frame>Multiple timepoints up to day 2</time_frame>
    <description>in study part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of methotrexate in plasma in presence/absence of BAY1834845</measure>
    <time_frame>Multiple timepoints up to day 2</time_frame>
    <description>in study part B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Treatment Emergent Adverse Events (TEAEs) in part A</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of TEAEs in part A</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of TEAEs in part B</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of TEAEs in part B</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Oral BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Part A, cross over sequence:
single oral dose of BAY1834845
single oral dose of BAY1834845 + i.v. BAY1834845
single oral dose of BAY1834845 under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral BAY1834845 + i.v. BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Part A, cross over sequence:
single oral dose of BAY1834845+ i.v. BAY1834845
single oral dose of BAY1834845
single oral dose of BAY1834845 under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study part B, cross over sequence:
single oral dose of methotrexate (MTX)
single oral dose of MTX + single oral dose of BAY1834845</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Methotrexate + oral BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study part B, cross over sequence:
single oral dose of methotrexate (MTX) + single oral dose of BAY1834845
single oral dose of MTX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1834845</intervention_name>
    <description>Single oral dose (IR [immediate release] tablets)</description>
    <arm_group_label>Oral BAY1834845</arm_group_label>
    <arm_group_label>Oral BAY1834845 + i.v. BAY1834845</arm_group_label>
    <arm_group_label>Oral Methotrexate</arm_group_label>
    <arm_group_label>Oral Methotrexate + oral BAY1834845</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1834845</intervention_name>
    <description>I.v. infusion of [13C6]-labeled BAY1834845</description>
    <arm_group_label>Oral BAY1834845</arm_group_label>
    <arm_group_label>Oral BAY1834845 + i.v. BAY1834845</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Single dose of commercially available MTX</description>
    <arm_group_label>Oral Methotrexate</arm_group_label>
    <arm_group_label>Oral Methotrexate + oral BAY1834845</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male; healthy according to complete medical history, physical examination, vital
             signs, 12-lead ECG and clinical laboratory tests as listed in the exclusion criteria
             given below.

          -  Age 18-50 years (inclusive) at the first screening visit.

          -  Body mass index: &gt;18 kg/m² and &lt;30 kg/m².

          -  Sexually active men must agree to practice adequate methods of contraception
             (protection).

        This applies for the time period between signing of the informed consent form and up to 90
        days after the last administration of the study drug(s).

        Exclusion Criteria:

          -  Any contraindications for intake of BAY 1834845 or methotrexate, gastrointestinal,
             liver, renal, lung or cardiovascular disorders, malignant tumors, known severe
             allergies, known or suspected immunodeficiency

          -  Medication history: drugs known to induce/inhibit liver enzymes

          -  Smoking

          -  Clinically relevant findings in

               -  physical

               -  ECG, blood pressure

               -  laboratory values

          -  Known hypersensitivity to study drug(s)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRAHealthSciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

